drugset / Trial / NCT02384070
Simplified Anti-Thrombotic Therapy for FFR
RandomizedParallel-groupTriple-blindDiagnostic
Summary
Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR calculation, no study has evaluated the optimal anti-thrombotic regimen in patients undergoing FFR. Therefore, the aim of the Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve (SMART-FFR) study was to evaluate the safety of using a simplified anti-thrombotic regimen with only upstream dual anti-platelet therapy (DAT) with aspirin and clopidogrel, compared with anticoagulation plus single- or- DAT therapy in patients with intermediate coronary artery stenosis undergoing FFR calculation during elective coronary angiography.
Timeline
- Start
- 2009-01
- Primary completion
- 2013-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 325 mg | — |
| Subject | Bivalirudin | Peptide | 1.75 mg/kg | Intravenous |
| Subject | Clopidogrel | Small molecule | 600 mg | — |